Olmesartan, sold under the brand name Benicar among others, is a medication used to treat high blood pressure. It is taken orally. Versions are available as the combination olmesartan/hydrochlorothiazide and olmesartan/amlodipine. It is available as a prodrug and is administered as olmesartan medoxomil, which is rapidly hydrolyzed by esterases in the gut wall and liver to the active angiotensin II type 1 receptor blocker olmesartan. Olmesartan is a selective AT1 receptor antagonist that reduces vasoconstriction and aldosterone secretion; pharmacokinetic properties include moderate oral bioavailability, peak plasma concentrations within about 1 to 3 hours, an elimination half-life commonly reported in the range of roughly 10 to 15 hours, and primary elimination as unchanged active moiety via biliary and renal routes. Clinical formulations include monotherapy and fixed-dose combinations with a thiazide diuretic or a calcium channel blocker to achieve complementary blood pressure control.
Parent: Olmesartan Medoxomil
Parent: Olmesartan Medoxomil
Parent: Olmesartan Medoxomil
Parent: Olmesartan Medoxomil
Parent: Olmesartan Medoxomil
Parent: Olmesartan Medoxomil
Parent: Olmesartan Medoxomil
Impurity control for olmesartan medoxomil follows ICH Q3A guidance and typical pharmacopeial practice; the qualification threshold is generally around 0.5 relative to daily dose considerations and the identification threshold around 0.1. Common related substances and degradants include the de-esterified active olmesartan (free acid), isomeric and stereochemical variants, medoxomil-derived fragments (cleavage products of the prodrug moiety), process-related intermediates and low-level residual solvents. Typical specification ranges used in manufacturing and quality control are individual identified impurities limited to approximately 0.1 to 0.5 percent by area or weight, individual unspecified impurities held at or below 0.1 percent, and total impurities commonly limited to about 1.0 percent or up to 2.0 percent depending on the monograph or dossier. Control strategies also address residual solvents under ICH Q3C, elemental impurities under ICH Q3D, and stability-indicating assay requirements to ensure any impurity above qualification thresholds is identified and evaluated for safety.
Olmesartan medoxomil is used to lower high blood pressure by blocking angiotensin II type 1 receptors, which reduces vasoconstriction and aldosterone-mediated sodium retention; it is prescribed as monotherapy or in fixed-dose combinations to improve blood pressure control.
Olmesartan medoxomil is usually taken once daily and can be taken with or without food; the optimal dosing time is one that supports consistent daily adherence, and any change in timing should be discussed with a prescriber.
Olmesartan is an effective angiotensin receptor blocker with a favorable efficacy and tolerability profile for many patients; whether it is an appropriate choice depends on individual clinical factors, comorbidities, concomitant medications and prescriber judgment.
No, olmesartan medoxomil is not a diuretic; it is an angiotensin II receptor blocker. Diuretics such as hydrochlorothiazide are sometimes combined with olmesartan in fixed-dose products to provide additive blood pressure lowering.
